Harvard Bioscience, Inc. (HBIO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Axogen, Inc.

Bioventus, Inc.

TELA Bio, Inc.

908 Devices, Inc.

Harvard Bioscience, Inc.

Butterfly Network, Inc.

Standard BioTools, Inc.

Allurion Technologies, Inc.

Celcuity, Inc.

Pulse Biosciences, Inc.

Jin Medical International Ltd.

Why is Harvard Bioscience, Inc. ?

Poor Management Efficiency with a low ROCE of 0.93%

The company has been able to generate a Return on Capital Employed (avg) of 0.93% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -3.07% over the last 5 years

With a growth in Net Profit of 131.28%, the company declared Very Positive results in Sep 25

RAW MATERIAL COST(Y) Fallen by -4.31% (YoY)
CASH AND EQV(HY) Highest at USD 14.26 MM
PRE-TAX PROFIT(Q) At USD -1.09 MM has Grown at 46.62%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -14.34%, its profits have risen by 55.1%

High Institutional Holdings at 76.89%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 9.94% over the previous quarter.

Below par performance in long term as well as near term

Along with generating -14.34% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Harvard Bioscience, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Harvard Bioscience, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Harvard Bioscience, Inc.

-14.34%

0.09

975.81%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-3.07%

EBIT Growth (5y)

-24.83%

EBIT to Interest (avg)

-0.06

Debt to EBITDA (avg)

7.24

Net Debt to Equity (avg)

2.15

Sales to Capital Employed (avg)

1.20

Tax Ratio

0.13%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

76.89%

ROCE (avg)

0.93%

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.59

EV to EBIT

-31.92

EV to EBITDA

10.93

EV to Capital Employed

1.20

EV to Sales

0.58

PEG Ratio

Dividend Yield

ROCE (Latest)

-3.74%

ROE (Latest)

-38.14%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -4.31% (YoY

CASH AND EQV(HY)

Highest at USD 14.26 MM

PRE-TAX PROFIT(Q)

At USD -1.09 MM has Grown at 46.62%

NET PROFIT(Q)

At USD -1.18 MM has Grown at 46.26%

-1What is not working for the Company

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.77 times

Here's what is working for Harvard Bioscience, Inc.

Pre-Tax Profit

At USD -1.09 MM has Grown at 46.62%

over average net sales of the previous four periods of USD -2.03 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -1.18 MM has Grown at 46.26%

over average net sales of the previous four periods of USD -2.2 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Cash and Eqv

Highest at USD 14.26 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -4.31% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Harvard Bioscience, Inc.

Inventory Turnover Ratio

Lowest at 1.77 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio